机构

• 上海药物研究所 [20]
• 广州生物医药与健康研... [2]
• 合肥物质科学研究院 [2]
• 上海生物化学与细胞生... [1]

采集方式

• OAI收割 [25]

内容类型

• 期刊论文 [22]
• 学位论文 [2]
• 会议论文 [1]

发表日期

• 2023 [1]
• 2022 [3]
• 2021 [1]
• 2020 [6]
• 2019 [5]
• 2018 [3]
• 更多

学科主题

• 药物化学 [2]

筛选

浏览/检索结果: 共25条，第1-10条 帮助 条数/页： 5101520253035404550556065707580859095100 排序方式： 请选择提交时间升序提交时间降序题名升序题名降序作者升序作者降序发表日期升序发表日期降序 Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo 期刊论文  OAI收割 JOURNAL OF CANCER, 2023, 卷号: 14, 期号: 1, 页码: 152-162 作者:  Lai, Mengzhen;  Zhang, Tao;  Chen, Hao;  Song, Peiran;  Tong, Linjiang   |  收藏  |  浏览/下载：111/0  |  提交时间：2023/04/10 fourth-generation EGFR inhibitor  EGFRC797S mutation  NSCLC  drug resistance  small molecular inhibitor   Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations br 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 65, 期号: 9, 页码: 6840-6858 作者:  Chen, Hao;  Lai, Mengzhen;  Zhang, Tao;  Chen, Yuqing   |  收藏  |  浏览/下载：23/0  |  提交时间：2022/08/16 Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-GenerationEpidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations 期刊论文  OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 65, 期号: 9, 页码: 6840-6858 作者:  Chen, Hao;  Lai, Mengzhen;  Zhang, Tao;  Chen, Yuqing;  Tong, Linjiang   |  收藏  |  浏览/下载：7/0  |  提交时间：2024/03/21 Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants 期刊论文  OAI收割 ACS MEDICINAL CHEMISTRY LETTERS, 2022, 页码: 7 作者:  Li, Shan;  Zhang, Tao;  Zhu, Su-Jie;  Lei, Chong;  Lai, Mengzhen   |  收藏  |  浏览/下载：25/0  |  提交时间：2022/06/15 Epidermal Growth Factor Receptor (EGFR)  Resistant Mutation  C797S  Antitumor   The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer 期刊论文  OAI收割 TRANSLATIONAL CANCER RESEARCH, 2021, 卷号: 10 作者:  Pan, Guoqiang;  Chen, Kaiyan;  Yu, Xiaoqing;  Sheng, Jiamin;  Fan, Yun   |  收藏  |  浏览/下载：50/0  |  提交时间：2021/11/01 Non-small cell lung cancer (NSCLC)  T790M abundance  droplet digital PCR (ddPCR)  next generation sequencing (NGS)  osimertinib   Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation 期刊论文  OAI收割 BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2020, 卷号: 30, 期号: 16, 页码: 6 作者:  Su, Zhicheng;  Yang, Tingyuan;  Wang, Jie;  Lai, Mengzhen;  Tong, Linjiang   |  收藏  |  浏览/下载：62/0  |  提交时间：2020/12/24 EGFR  NSCLC  C797S   Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance 期刊论文  OAI收割 MOLECULAR CANCER, 2020, 卷号: 19, 期号: 1, 页码: 15 作者:  Zhang, Tao;  Qu, Rong;  Chan, Shingpan;  Lai, Mengzhen;  Tong, Linjiang   |  收藏  |  浏览/下载：79/0  |  提交时间：2020/07/01 Non-small cell lung cancer (NSCLC)  EGFR T790M  Small-molecule inhibitor  Drug resistance  Ack1   Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway 期刊论文  OAI收割 ACTA PHARMACOLOGICA SINICA, 2020 作者:  Chen, Cheng;  Cheng, Chuan-dong;  Wu, Hong;  Wang, Zuo-wei;  Wang, Li   |  收藏  |  浏览/下载：22/0  |  提交时间：2020/11/26 glioblastoma  osimertinib  temozolamide  MAPK-signaling pathway  MNK  eukaryotic translation initiation factor 4E   2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidines as new reversible inhibitors of EGFR C797S (Cys797 to Ser797) mutant 期刊论文  OAI收割 CHINESE CHEMICAL LETTERS, 2020, 卷号: 31, 期号: 5, 页码: 1281-1287 作者:  Hu, Xianglong;  Xun, Qiuju;  Zhang, Tao;  Zhu, Su-Jie;  Li, Qian   |  收藏  |  浏览/下载：81/0  |  提交时间：2020/07/01 EGFR(C797S) mutant  SARs  2-Oxo-3,4-dihydropyrimido[4,5-d] pyrimidine  Clinical resistance  Fourth-generation inhibitors   Design and synthesis of selective degraders of EGFR(L858R/T790M) mutant 期刊论文  OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 卷号: 192, 页码: 14 作者:  Zhang, Xin;  Xu, Fang;  Tong, Linjiang;  Zhang, Tao;  Xie, Hua   |  收藏  |  浏览/下载：68/0  |  提交时间：2020/07/01 Epidermal growth factor receptor (EGFR)  Resistance  Proteolysis targeting chimera (PROTAC)  Protein degradation